Filing Flows › AbCellera Biologics (ABCL) › Q4 2024
AbCellera Biologics (ABCL) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Feb 27, 2025
AbCellera Biologics (ABCL) reported revenue of $5.0M for the fourth quarter 2024 (Q4 2024), -45% from a year earlier and -22% from the quarter before.
AbCellera Biologics, Q4 2024: revenue $5.0M (-45% year over year), net loss $34.2M, operating cash flow −$8.0M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $5.0M | -22% | -45% |
| Operating profit | −$72.8M | — | — |
| Net earnings | −$34.2M | — | — |
| Operating cash flow | −$8.0M | — | — |
What changed
Revenue was $5.0M in Q4 2024, down 45% year over year and down 22% from the previous quarter. Research fees was the largest line at 94% of revenue.
Operating costs exceeded revenue by $72.8M, an operating margin of -1440.7%. Total costs grew 3% against a revenue fall of 45%. The fastest-growing cost line was Other operating costs (+67%). The quarter ended with a net loss of $34.2M, narrower than the previous quarter's $51.1M loss. Non-operating items added $25.9M, -55% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$8.0M. Non-cash charges added back $15.2M of share-based compensation. Working capital and other items added $11.0M. Capital expenditures of $15.6M exceeded it, leaving free cash flow of −$23.6M.
Questions
What was AbCellera Biologics' revenue in the fourth quarter 2024?
AbCellera Biologics (ABCL) reported revenue of $5.0M for the fourth quarter 2024 (Q4 2024), -45% from a year earlier and -22% from the quarter before.